Liamid

Glibenclamide, the active ingredient in Liamid, is a second‑generation sulfonylurea presented as an oral tablet for oral administration. It acts by enhancing insulin secretion from pancreatic β‑cells, thereby reducing elevated blood glucose levels. Liamid is indicated for the treatment of type 2 diabetes mellitus in adult patients requiring oral hypoglycemic therapy.

GNH USA supplies Liamid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels aligned to EU regulatory standards. The company ensures product quality through rigorous testing and adherence to Good Manufacturing Practices.

Liamid (glibenclamide) is used within the sulfonylurea class to improve glycaemic control in patients with type 2 diabetes mellitus.

- Type 2 diabetes mellitus (adult): lowers fasting and post‑prandial glucose by stimulating insulin release. - Hyperglycaemia secondary to type 2 diabetes: helps achieve target HbA1c levels when diet and exercise are insufficient. - Adjunct to diet and exercise in type 2 diabetes: provides additional glucose‑lowering effect alongside lifestyle measures.

Common Side Effects: - Hypoglycaemia: feeling of shakiness, sweating, or confusion due to low blood sugar. - Weight gain: modest increase in body weight associated with improved glycaemic control. - Nausea or abdominal discomfort: mild gastrointestinal upset. - Skin rash or pruritus: mild dermatologic reactions. - Headache: transient head discomfort.

Serious or Rare Side Effects: - Severe hypoglycaemia: can lead to loss of consciousness or seizures. - Allergic reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hemolytic anaemia or other blood dyscrasias. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Cardiovascular events in susceptible patients.

Before initiating therapy, consider the following precautions: - Monitor blood glucose regularly: adjust dose based on glycaemic response. - Adjust dose in renal impairment: reduced clearance may increase risk of hypoglycaemia. - Use caution in elderly patients: increased sensitivity to insulin‑secretagogue effects. - Avoid in patients with known sulfonylurea hypersensitivity: risk of severe allergic reactions. - Pregnancy and lactation: safety not established, consult a physician before use. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Glibenclamide may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concomitant use with insulin or other sulfonylureas: markedly increased risk of severe hypoglycaemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone): may raise glibenclamide plasma levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - CYP2C9 inducers (e.g., rifampicin, carbamazepine): may reduce drug efficacy. - Thiazide diuretics: can attenuate glucose‑lowering effect and increase blood pressure. - NSAIDs or ACE inhibitors: may affect renal function, altering glibenclamide clearance.